BioValues

Biotech investor. Tend to focus on contrarian names, so I'm probably buying what you are selling/hating on. All tweets are my opinions only.

[BioValues @BioValues]

$CRBP good to see, especially given he just joined mgmt and obesity data is ~3 months out. High caliber background imo:

[BioValues @BioValues]

$CRBP CBO buys 13,500 open market: https://t.co/V1P0yNTE28

[BioValues @BioValues]

@BOSSTRADING0 actually CB1 receptor data, but yes, good to see!

[CorporateActionsUSA @actions_usa]

Chief Business Officer Saxena Nishant C just executed a significant discretionary open-market purchase of $CRBP.

- Volume: 13,500
- Holdings Impact: 15.2% of total position
- 10b5-1 Plan: No
- Average Price: $7.50
- Total Capital Deployed: $101,218.50
- Liquidity Impact: 2.32% of 30-day ADTV

CONVICTION SCORE: 8/10

MARKET THESIS: This opportunistic buy by the Chief Business Officer signals internal confidence ahead of the upcoming ASCO 2026 conference. The company has confirmed a registration path with the FDA for CRB-701 in HNSCC and cervical cancer, and the insider is increasing his stake by 15.2% just as the firm prepares to present mature clinical data. By bypassing a 10b5-1 plan, the executive is signaling that the current valuation does not reflect the clinical potential of the lead asset.

Are you front-running this C-suite accumulation or waiting for the ASCO data dump? Your thoughts? 👇

#CRBP #Biotech #InsiderBuying #WallStreet

🤖 AI-Curated Data Pipeline | Not Financial Advice

[BioValues @BioValues]

@RichardTip17589 @ElMonoGran42994 Exited after I saw RA selling some. Will reenter at some point

[BioValues @BioValues]

$CRBP if you believe obesity has a chance of hitting this is the area to buy IMO (stock at 52 week low support). These are the generational opportunities that stand out to me. Remains largest position and plan to hold into obesity given the sheer upside vs limited downside

[BioValues @BioValues]

$CRBP looks like some smart money agreeing with me. Nice rally off the $7 line and closing near highs with a big hammer candle:

[BioValues @BioValues]

@ElMonoGran42994 when market is running the stock down into a catalyst and at 52 week lows, below cash, that's where I load the hell up. Contrarian always for the win, that's how I am up 2000% past year

[BioValues @BioValues]

@ElMonoGran42994 you have no idea if safety is a dud lol. CEO knows the blinded data and sounds confident and said no serious AEs

[BioValues @BioValues]

@bioinvestor24 exactly. I love these setups. Buy what people hate/don't expect to win. Contrarian positive outcomes that could provide enormous upside. That's why I don't play PRAX, ABVX, CELC, etc.

[BioValues @BioValues]

@bioinvestor24 they might care if data comes in compelling

[BioValues @BioValues]

@ElMonoGran42994 ACET 2nd largest position. These two will be life changing for me after their data, especially given both deep under cash with max pessimism going into data (aka no expectations)

[BioValues @BioValues]

Good day to go shopping for biotechs that are under cash with data coming later this summer: $ACET $CRBP IMO

[BioValues @BioValues]

@ElMonoGran42994 @BioLobotomy @TKkamen exited earlier, on to the next

[BioValues @BioValues]

$NXTC was at $10 and now mid $6s and data is not even formally out yet, continue to add ahead of ASCO

[BioValues @BioValues]

@financebully regardless of CB1, it's cheap for ADC, and would be dirt cheap if it hits

[BioValues @BioValues]

$CRBP I have no idea what the upside is if CB1 obesity hits, but at $7s valuation, it's got to be absolutely massive. Things could get absolutely wild here in 3 months and people will be looking back and be thinking of today

[BioValues @BioValues]

$ACET SLE/LN data closing in fast and stock starting to move. Remember, these guys have a super tiny float and $14/share in cash going into the data event. 2nd largest position behind $CRBP

[BioValues @BioValues]

@BioLobotomy @TKkamen Yes

[BioValues @BioValues]

@glbeaty I think many feel that there will be unacceptable AEs. I'm hopeful they won't see that

[BioValues @BioValues]

$CRBP let's pretend they do hit in CB1 obesity, what is the upside? 3x 5x 10x+? Remember, NVO lost $30B market cap. Downside would be maybe $1 from here? Have to have a floor value given cash/CRB-701. Has there even been such an asymmetric opportunity on risk/reward in biotech?

[BioValues @BioValues]

@masonat7 @jesse_brodkin CEO has made some interesting bullish comments, something to the effect of: "I think we could be surprised by the magnitude of weight-loss"